Genmab — September 2016
-
-
ASH abstract datoer: http://www.hematology.org/Annual-Meeting/Abstracts/2853.aspx
-
-
ASCLEPIOS II rekrutterer. https://clinicaltrials.gov/ct2/show/NCT02792231?term=ofatumumab&recr=Open&rank=11
-
I forbindelse med Jan van de Winkels præsentation hos Morgan Stanley af Genmab, nævnte han følgende om deres hexybody-program: "We have presented that data, that pre-clinical data, at different scientific conferences this year, many times in key-note lectures, and some of the original pharma and biotech companies working on the original antibodies immediately wanted to partner the hexybody molecules because of the pre-clinical profile and luckily we have the luxury that we can hold on to them...
-
De selskaber, som Jan henviser til, som øjeblikkelig har taget kontakt til Genmab med henblik på at indgå partnerskab om deres hexabody, er selskaber, der selv har forsøgt at lave hexabodies med samme molekyle, og som har brændt op til 100 mio. dollars af, men som ved efterfølgende forsøg har fundet ud af, at deres antibodies ikke havde tilstrækkelig effekt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind